CDR-Life Updates Pipeline Progress for M-gager® Solid Tumor Treatments

CDR-Life has announced key advancements in its M-gager® programs targeting solid tumors, highlighting notable progress in its mission to develop innovative antibody fragment-based immunotherapies for challenging cancers. First Patient Dosed with CDR404 CDR-Life has dosed its first patient with CDR404,…

Read MoreCDR-Life Updates Pipeline Progress for M-gager® Solid Tumor Treatments

Rising Pharmaceuticals Launches Edetate Calcium Disodium Injection in the U.S.

Rising Pharmaceuticals, Inc. has announced the commercial launch of Edetate calcium disodium injection. Despite a current shortage of this product in the U.S., Rising’s version remains available. Rising Pharmaceuticals, Inc. has announced the availability of Edetate calcium disodium injection, which…

Read MoreRising Pharmaceuticals Launches Edetate Calcium Disodium Injection in the U.S.

Masimo and Google Team Up to Create Reference Platform for Advanced Wear OS Smartwatches

Masimo (NASDAQ: MASI), a leading innovator in medical technology, has announced a new partnership with Google to develop a reference platform for Wear OS by Google™ smartwatches. This collaboration will integrate Masimo’s advanced biosensing technologies, honed through decades of hospital…

Read MoreMasimo and Google Team Up to Create Reference Platform for Advanced Wear OS Smartwatches

SamanTree Medical’s Histolog® Scanner Receives FDA Clearance, Revolutionizing Tissue Imaging in the U.S.

SamanTree Medical, a pioneer in surgical imaging technology, has announced that its Histolog® Scanner has received FDA 510(k) clearance. This groundbreaking Swiss device offers real-time, high-resolution imaging of fresh tissue surfaces, enabling detailed visualization of internal microstructures such as cells,…

Read MoreSamanTree Medical’s Histolog® Scanner Receives FDA Clearance, Revolutionizing Tissue Imaging in the U.S.

Japan Approves CSL and Arcturus’ Updated mRNA COVID-19 Vaccine for JN.1 Strain

CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. The new vaccine is designed to protect against the JN.1 lineage of Omicron…

Read MoreJapan Approves CSL and Arcturus’ Updated mRNA COVID-19 Vaccine for JN.1 Strain

Advanced eClinical Training and The Education Fund Partner to Enhance Healthcare Worker Education

Advanced eClinical Training (ACT), a top provider of online career certification, has joined forces with the SEIU-UHW West & Joint Employer Education Fund (The Education Fund), which offers employer-funded education, training, and career support for union members in healthcare. This…

Read MoreAdvanced eClinical Training and The Education Fund Partner to Enhance Healthcare Worker Education

ENHERTU® Shows Strong Clinical Activity in HER2+ Metastatic Breast Cancer with Brain Metastases

Results from the DESTINY-Breast12 phase 3b/4 trial reveal that ENHERTU® (trastuzumab deruxtecan) demonstrated significant clinical activity in HER2-positive metastatic breast cancer patients with brain metastases who had received up to two prior lines of therapy. These findings will be presented…

Read MoreENHERTU® Shows Strong Clinical Activity in HER2+ Metastatic Breast Cancer with Brain Metastases

LifestyledAI, Dongguk University, and UMUST R&D Partner to Drive Global AI and Healthcare Innovation

On August 28, 2024, Dongguk University Startup Technology Institute, LifestyledAI Co., Ltd., and UMUST R&D signed a joint MOU to collaborate on advancing global deep tech and healthcare initiatives. The partnership will leverage LifestyledAI’s innovative, proprietary AI technologies, currently patent-pending,…

Read MoreLifestyledAI, Dongguk University, and UMUST R&D Partner to Drive Global AI and Healthcare Innovation

Massive Bio and Foundation Medicine Partner to Enhance Cancer Clinical Trial Access

Massive Bio, an AI-powered clinical trial matching platform, and Foundation Medicine have announced a strategic partnership to expand patient access to advanced clinical trials. The collaboration combines Massive Bio’s patient-matching technology with Foundation Medicine’s expertise in next-generation sequencing (NGS) and…

Read MoreMassive Bio and Foundation Medicine Partner to Enhance Cancer Clinical Trial Access